Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mo...
Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mouse tumors
About this item
Full title
Author / Creator
Publisher
Greece
Journal title
Language
English
Formats
Publication information
Publisher
Greece
Subjects
More information
Scope and Contents
Contents
The efficacy of programmed cell death‑ligand 1 (PD‑L1)/programmed cell death protein 1 (PD‑1) blockade therapy has been demonstrated but is limited in patients with PD‑L1
or immune desert tumors. This limitation can be overcome by combination therapies that include anti‑vascular endothelial growth factor (VEGF) therapy. Such combinations have be...
Alternative Titles
Full title
Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1 low and immune desert‑like mouse tumors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_34958105
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_34958105
Other Identifiers
ISSN
1021-335X
E-ISSN
1791-2431
DOI
10.3892/or.2021.8247
